Study guide
3.4 Performance Status, Frailty & Geriatric Assessment
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
3.4 Performance Status, Frailty & Geriatric Assessment
Key Takeaways Explain This Topic AI
ECOG performance status runs from 0 (fully active) to 5 (deceased); the pivotal distinction between ECOG 2 and ECOG 3 is whether the patient is up and about, or confined to bed or chair, for more than 50% of waking hours.
Most cytotoxic combination regimens and most clinical trials require ECOG 0 to 1 or a Karnofsky score of at least 70, and ECOG 3 to 4 patients generally derive toxicity without survival benefit from aggressive cytotoxic therapy.
Performance status is prognostic but insensitive to frailty, so an older adult with ECOG 1 can still be at high risk for severe toxicity.
The CARG and CRASH scores predict grade 3 to 5 chemotherapy toxicity in older adults more accurately than ECOG or Karnofsky status and should inform dose and regimen selection.
ASCO recommends geriatric assessment for patients aged 65 and older receiving systemic therapy, covering function, comorbidity, cognition, nutrition, psychological state, social support, and polypharmacy.
Last updated: August 2026
3.4 Performance Status, Frailty & Geriatric Assessment
Blueprint focus: ONCC Domain I.B.2 — Patient assessment, including performance status scales. Functional assessment is the gatekeeper for every treatment decision in this guide: it determines trial eligibility, regimen intensity, dose, and whether disease-directed therapy is appropriate at all.
Why Function Predicts Outcome
Performance status is one of the strongest independent prognostic variables in oncology, often outweighing stage in patients with advanced disease. It measures physiologic reserve — the capacity to absorb the insult of cytotoxic therapy and recover. A patient who cannot climb a flight of stairs is unlikely to recover from grade 4 neutropenia without a life-threatening infection.
Performance status also carries ethical weight . Offering aggressive chemotherapy to a patient with ECOG 4 disease creates the appearance of choice while delivering toxicity without benefit. Recognizing that boundary and converting the conversation to goals of care is core APRN practice.
The Two Standard Scales
- ECOG Definition Approximate Karnofsky
- 0 Fully active, able to carry on all pre-disease activity without restriction 100 to 90
- 1 Restricted in physically strenuous activity but ambulatory and able to do light or sedentary work 80 to 70
2 Ambulatory and capable of all self-care , unable to carry out any work activities, up and about more than 50% of waking hours 60 to 50
- 3 Capable of only limited self-care , confined to bed or chair more than 50% of waking hours 40 to 30
- 4 Completely disabled, no self-care, totally confined to bed or chair 20 to 10
- 5 Deceased 0
The ECOG 2 versus 3 boundary is the most heavily tested item on the scale. Both patients have significant impairment. The discriminator is the proportion of waking hours spent up and about versus confined, and whether self-care is complete (2) or only partial (3).
Karnofsky uses 10-point increments from 100 down to 0 and is more granular, which makes it common in transplant eligibility and palliative research. Note the direction: a higher Karnofsky score means better function, the reverse of ECOG.
The Palliative Performance Scale (PPS) extends Karnofsky by adding ambulation, activity and evidence of disease, self-care, intake, and level of consciousness. It is widely used to support hospice prognostication, where a PPS at or below 50% to 40% with declining intake supports a limited prognosis.
How Performance Status Drives Treatment Decisions
Clinical trials almost always require ECOG 0 to 1 , occasionally ECOG 2 for supportive-care or single-agent studies.
Intensive combination cytotoxic regimens generally require ECOG 0 to 1 or Karnofsky at least 70 to 80.
Single-agent or attenuated regimens and most targeted oral agents may be reasonable at ECOG 2.
ECOG 3 to 4 patients typically receive best supportive care with palliative intent; immune checkpoint inhibitors are not an exception, since response rates fall sharply and immune-related toxicity is poorly tolerated in this group.
Allogeneic transplant additionally requires a comorbidity index assessment such as the HCT-CI, because performance status alone underestimates organ-specific risk.
The Limits of Performance Status in Older Adults
Performance status was designed decades ago in trial populations that were younger and healthier than the patients now treated. It is insensitive to frailty : an older adult can look like ECOG 1 in clinic and still have impaired instrumental activities of daily living, undiagnosed cognitive impairment, poor nutrition, falls, and eight interacting medications. That patient's real risk of grade 3 to 5 toxicity is much higher than the ECOG score suggests.
ASCO recommends geriatric assessment for patients aged 65 and older who are being considered for systemic therapy.
Domains of the comprehensive geriatric assessment
Domain Instruments commonly used What an abnormal result changes
Functional status ADLs, IADLs, Timed Up and Go, number of falls in 6 months Home support, physical therapy, dose attenuation
Comorbidity Charlson index, CIRS-G Drug selection, organ-function-based dosing
Cognition Mini-Cog, MoCA, Blessed Orientation-Memory-Concentration Capacity to consent, adherence support, caregiver involvement
Nutrition Unintentional weight loss, body mass index, Mini Nutritional Assessment Dietitian referral, mucositis and cachexia risk
Psychological Geriatric Depression Scale, distress thermometer Psycho-oncology referral, treatment of depression before therapy
Social support Living situation, caregiver availability, transport Feasibility of outpatient regimens and oral agents
Polypharmacy Full medication reconciliation, Beers criteria Deprescribing, anticipation of drug–drug interactions
Validated Toxicity Prediction Tools
Two calculators outperform performance status for predicting chemotherapy toxicity in older adults, and both are fair game on the exam.
CARG (Cancer and Aging Research Group) score — combines age, tumor type, planned chemotherapy dose and number of drugs, hemoglobin, creatinine clearance, hearing, falls, need for help with medications, ability to walk a block, and social activity. It stratifies risk of grade 3 to 5 toxicity into low, intermediate, and high.
CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) score — produces separate estimates for hematologic and non-hematologic toxicity, using diastolic blood pressure, instrumental ADLs, lactate dehydrogenase, cognition, nutrition, and the regimen's own toxicity profile.
A high CARG score does not mandate withholding treatment. It should drive a concrete plan: attenuated starting dose, a less toxic regimen, primary growth factor prophylaxis, closer monitoring intervals, home support, and an explicit re-evaluation point.
Documenting the Assessment
Record the numeric score, the scale used, and the observation that justifies it — "ECOG 2: ambulatory, independent in all self-care, stopped working, rests approximately 4 hours during the day." A bare number without narrative is not defensible when it is later used to justify or withhold therapy. Reassess at every cycle, because a decline of one ECOG level during treatment is a stronger signal to change course than any single laboratory value.